5 results on '"Patrick, McPhail"'
Number of results to display per page
Search Results
2. Trusted Partnerships in the Faith Community Facilitate Awareness and Recruitment of African Americans for Alzheimer’s Disease Studies
- Author
-
Williams, Kelvin, primary, Henderson, Shelby, additional, Lloyd, Shawnta', additional, Caban‐Holt, Allison M, additional, Starks, Takiyah D., additional, Martin, Patrick McPhail, additional, Bozoki, Andrea C., additional, Price, Stephen Russ, additional, Plassman, Brenda L, additional, Welsh‐Bohmer, Kathleen A., additional, and Byrd, Goldie S., additional
- Published
- 2022
- Full Text
- View/download PDF
3. The NC Registry for Brain Health: Increasing Access to Brain Health Information and Research in Underserved & Under‐represented Communities.
- Author
-
Chanti‐Ketterl, Marianne, Dewees, Rachel A, Bozoki, Andrea, Price, Stephen Russ, Martin, Patrick McPhail, Edmonds, Henry, Adams, Latorius S, Williams, Kelvin, Gaven, Julie, Matchar, Bobbi, Herron, Susan, Ries, Michelle G, Plassman, Brenda L, Byrd, Goldie S., and Welsh‐Bohmer, Kathleen A.
- Abstract
Background: Diverse racial/ethnic representation in scientific studies is crucial for generalizability of results and development of potentially effective treatments. Racially diverse registries with research ready individuals have the potential to fill this gap. However, despite having signed up as part of a research registry and being invited to participate in clinical trials, many do not participate. To better understand research participation, the NC Registry for Brain Health surveyed its members to identify the characteristics of those likely to participate in research studies, their views on research, expectations when joining the group, and impediments to participation. Method: The NC Registry for Brain Health has been state‐funded since 2018 with goals of increasing access for all to information and research opportunities in brain health. Focused recruitment to under‐served and under‐represented groups across the State occurs through community outreach events sponsored by a five member university network. An email survey was sent to the 5,946 Registry members enrolled as of October 15, 2021. Result: Approximately 10% (n = 576) responded to this anonymized survey. Most were older women with high levels of formal education (Table 1). Despite the Registry's demographics of 28% African American enrollees, only 8% of the survey respondents self‐identified as African Americans. Most individuals joined the Registry for the joint purpose of getting involved in research and receiving information about brain health (75%). When asked to describe what "brain health research" means, most reported studies involving dementia risk factors and memory testing. All participants had been approached to get involved in studies, but only 60% recalled getting an email invitation. The biggest impediment noted for participating in studies was inconvenient appointment times. The participants also wanted more available studies and more information about the opportunities. Conclusion: This study suggests that most participants in the Registry are seeking to be informed about brain health and have access to research opportunities at times convenient with their schedules. There was an observed gap between African Americans enrolled in the research registry and those who participated in the survey. Addressing gaps in research involvement of under‐represented groups in research is necessary to achieve inclusive representative science. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings
- Author
-
Alexandra, Calmy, Eric, Balestre, Fabrice, Bonnet, Andrew, Boulle, Eduardo, Sprinz, Robin, Wood, Eric, Delaporte, Eugène, Messou, James, McIntyre, Kamal Marhoum, El Filali, Mauro, Schechter, N, Kumarasamy, David, Bangsberg, Patrick, McPhail, Stefaan, Van Der Borght, Carlos, Zala, Matthias, Egger, Rodolphe, Thiébaut, François, Dabis, HIV Unit, Geneva University Hospital, Epidémiologie et Biostatistique [Bordeaux], Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Université Bordeaux Segalen - Bordeaux 2, Service de Médecine Interne et Maladies Infectieuses, CHU Bordeaux [Bordeaux], School of Public Health and Family Medicine, University of Cape Town, South Brazil HIV Cohort, Hospital de Clínicas de Porto Alegre, Gugulethu ART Programme, Institut de Recherche pour le Développement (IRD), Centre de Prise en Charge, de Recherche et de Formation sur le VIH/SIDA, CePReF, Perinatal HIV Research Unit, Operational Research on ART (OPERA), Service des Maladies Infectieuses, Hôpital Ibn Rochd, Rio HIV Cohort, YRG Centre for AIDS Research and Education, Immune Suppression Syndrome Clinic (ISS), Helen Joseph Hospital Themba Lethu Clinic, Heineken International Health Affairs, Prospective Evaluation in the Use and Monitoring of Antiretrovirals in Argentina, PUMA, Institute of Social and Preventive Medicine (ISPM), University of Bern, The ART-LINC of IeDEA Collaboration was funded by the United States National Institute of Health (NIH - Office of AIDS Research) together with the French Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS - grants 12101 and 12138). The IeDEA network is now funded through collaborative agreements by the National Cancer Institute (NCI), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Allergy And Infectious Diseases (NIAID)., for the ART-LINC of IeDEA Collaboration (Asia, South America, East, Southern and West Africa), Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), BMC, Ed., Department of Public Health and Family Medicine, and Faculty of Health Sciences
- Subjects
Male ,CD4 slope ,HIV Infections ,030312 virology ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Medicine ,030212 general & internal medicine ,Cd4 cell count ,Stage (cooking) ,ddc:616 ,0303 health sciences ,Terapia anti-retroviral de alta atividade ,3. Good health ,HIV Infections/drug therapy/immunology ,RNA, Viral/genetics ,Infectious Diseases ,HIV-RNA threshold ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,RNA, Viral ,Female ,low or moderate-level viremia ,Research Article ,Adult ,Resource limited settings ,medicine.medical_specialty ,Anti-HIV Agents ,CD4 cell counts ,Viremia ,CD4 count ,Anti-retrovirais ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,Internal medicine ,Humans ,lcsh:RC109-216 ,In patient ,business.industry ,medicine.disease ,Antiretroviral therapy ,Contagem de linfócito CD4 ,CD4 Lymphocyte Count ,Regimen ,Institutional repository ,Antiretroviral treatment (ART) ,Anti-HIV Agents/therapeutic use ,Immunology ,HIV-1 ,business ,Limited resources - Abstract
Background Changes in CD4 cell counts are poorly documented in individuals with low or moderate-level viremia while on antiretroviral treatment (ART) in resource-limited settings. We assessed the impact of on-going HIV-RNA replication on CD4 cell count slopes in patients treated with a first-line combination ART. Method Naïve patients on a first-line ART regimen with at least two measures of HIV-RNA available after ART initiation were included in the study. The relationships between mean CD4 cell count change and HIV-RNA at 6 and 12 months after ART initiation (M6 and M12) were assessed by linear mixed models adjusted for gender, age, clinical stage and year of starting ART. Results 3,338 patients were included (14 cohorts, 64% female) and the group had the following characteristics: a median follow-up time of 1.6 years, a median age of 34 years, and a median CD4 cell count at ART initiation of 107 cells/μL. All patients with suppressed HIV-RNA at M12 had a continuous increase in CD4 cell count up to 18 months after treatment initiation. By contrast, any degree of HIV-RNA replication both at M6 and M12 was associated with a flat or a decreasing CD4 cell count slope. Multivariable analysis using HIV-RNA thresholds of 10,000 and 5,000 copies confirmed the significant effect of HIV-RNA on CD4 cell counts both at M6 and M12. Conclusion In routinely monitored patients on an NNRTI-based first-line ART, on-going low-level HIV-RNA replication was associated with a poor immune outcome in patients who had detectable levels of the virus after one year of ART.
- Published
- 2012
- Full Text
- View/download PDF
5. Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa
- Author
-
Luis J. Montaner, Pam Michelow, Anna-Lise Williamson, Allen C Rinas, Ian Sanne, Bruce R. Allan, Simon Levin, Khumbuzile Zungu, Charles van der Horst, Patrick McPhail, and Cynthia Firnhaber
- Subjects
Adult ,medicine.medical_specialty ,Histology ,Adolescent ,Population ,Papanicolaou stain ,HIV Infections ,Article ,Pathology and Forensic Medicine ,South Africa ,Young Adult ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,Antiretroviral Therapy, Highly Active ,Epidemiology ,Prevalence ,Medicine ,Humans ,Sida ,education ,Papillomaviridae ,Aged ,Vaginal Smears ,education.field_of_study ,biology ,business.industry ,Papillomavirus Infections ,virus diseases ,General Medicine ,Odds ratio ,Middle Aged ,biology.organism_classification ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,CD4 Lymphocyte Count ,Cohort ,Immunology ,DNA, Viral ,Female ,Viral disease ,business ,Papanicolaou Test - Abstract
Objective To evaluate the epidemiology of the human papillomavirus (HPV) type and correlate it with the Papanicolaou smears in human immunodeficiency virus-seropositive women in Johannesburg, South Africa. Study Design In a cohort of 148 women, HPV DNA testing was performed with the Roche HPV genotyping test (Branchburg, New Jersey, U.S.A.). Papanicolaou smears were performed by standard cytology utilizing 2001 Bethesda reporting guidelines. Results The average age and CD4 count of the participants was 35 years and 255 cells per mm 3 , respectively. Fifty-four percent had abnormal Papanicolaou smears; 66% of the abnormal cytology was low grade changes, with 33 % assessed as having high grade changes. HPV DNA was found in 95% of the 148 subjects assessed, with 83% having 1 or more HPV oncogenic types. Common oncogenic types were 16, 35, 53 and 18. When HPV results were stratified by CD4, there was a significant risk of an oncogenic HPV type in women with CD4
- Published
- 2009
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.